Overview

Doxil, Bevacizumab and Temsirolimus Trial

Status:
Completed
Trial end date:
2019-03-28
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer that has spread or is unable to be surgically removed. The safety and effectiveness of this combination of drugs will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Antibodies
Antibodies, Monoclonal
Bevacizumab
Doxorubicin
Everolimus
Liposomal doxorubicin
Sirolimus